Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma
- 15 June 2013
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (10) , 1621-1625
Abstract
Background: Patients with metastatic, progressive or recurrent Ewing sarcoma (ES) have a dismal outcome. The combination of irinotecan and temozolomide has been proposed as an effective salvage regimen for some pediatric malignancies. Thus, we sought to evaluate this combination with vincristine for patients with relapsed and refractory ES.Materials and Methods: Twenty‐two patients with relapsed or refractory ES were treated with the combination of vincristine (1.5 mg/m2 i.v. day 1), irinotecan (50 mg/m2/day i.v. days 1–5) and temozolomide (125 mg/m2/day p.o. days 1–5) (VIT) during the period 2008–2012. All toxicities were documented.Results: A total of 91 cycles (median 4.1 cycles/patient) were administered. A complete response (CR) was achieved in five patients, partial response (PR) in seven patients, stable disease (SD) in three patients, and progression disease (PD) in seven patients, with an overall response rate of 68.1%. Median time to progression was 3.0 months (range 1.1–37.1 months). Five patients (22.7%) are alive with no evidence of disease with a median follow‐up of 10.3 months (range 2.1–46.5); four of them received consolidation with high‐dose chemotherapy and autologous hematopoietic stem cell transplant after responding to VIT. Outcome was better for patients with relapsed ES compared with patients who progressed to initial therapy (estimated 2 year overall survival 36.4% vs. 0%, respectively). There were no significant toxicities.Conclusions: The shorter, 5‐day VIT regimen is an active and well‐tolerated regimen in refractory ES. This combination deserves further investigation in the upfront management of patients with metastatic disease. Pediatr Blood Cancer 2013;60:1621–1625.Keywords
Funding Information
- Children's Medical Care Foundation
This publication has 31 references indexed in Scilit:
- Risk of recurrence and survival after relapse in patients with Ewing sarcomaPediatric Blood & Cancer, 2011
- Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 TrialJournal of Clinical Oncology, 2010
- Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experiencePediatric Blood & Cancer, 2009
- Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk PatientsJournal of Clinical Oncology, 2008
- Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2008
- Analysis of prognostic factors in ewing sarcoma family of tumorsCancer, 2007
- Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcomaPediatric Blood & Cancer, 2005
- Temozolomide in resistant or relapsed pediatric solid tumorsPediatric Blood & Cancer, 2005
- Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcomaMedical and Pediatric Oncology, 2003
- Survival after recurrence of Ewing TumorsCancer, 2002